Literature DB >> 17224909

Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6.

S Camus1, S Menéndez, C F Cheok, L F Stevenson, S Laín, D P Lane.   

Abstract

In vitro, high-risk human papillomavirus E6 proteins have been shown, in conjunction with E6-associated protein (E6AP), to mediate ubiquitination of p53 and its degradation by the 26S proteasome by a pathway that is thought to be analogous to Mdm2-mediated p53 degradation. However, differences in the requirements of E6/E6AP and Mdm2 to promote the degradation of p53, both in vivo and in vitro, suggest that these two E3 ligases may promote p53 degradation by distinct pathways. Using tools that disrupt ubiquitination and degradation, clear differences between E6- and Mdm2-mediated p53 degradation are presented. The consistent failure to fully protect p53 protein from E6-mediated degradation by disrupting the ubiquitin-degradation pathway provides the first evidence of an E6-dependent, ubiquitin-independent, p53 degradation pathway in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17224909      PMCID: PMC2742713          DOI: 10.1038/sj.onc.1210188

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

Review 1.  The unfolding of substrates and ubiquitin-independent protein degradation by proteasomes.

Authors:  N Benaroudj; E Tarcsa; P Cascio; A L Goldberg
Journal:  Biochimie       Date:  2001 Mar-Apr       Impact factor: 4.079

2.  Molecular characterization of the thermosensitive E1 ubiquitin-activating enzyme cell mutant A31N-ts20. Requirements upon different levels of E1 for the ubiquitination/degradation of the various protein substrates in vivo.

Authors:  C Salvat; C Acquaviva; M Scheffner; I Robbins; M Piechaczyk; I Jariel-Encontre
Journal:  Eur J Biochem       Date:  2000-06

3.  Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.

Authors:  D Xirodimas; M K Saville; C Edling; D P Lane; S Laín
Journal:  Oncogene       Date:  2001-08-16       Impact factor: 9.867

Review 4.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.

Authors:  Michael H Glickman; Aaron Ciechanover
Journal:  Physiol Rev       Date:  2002-04       Impact factor: 37.312

5.  Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells.

Authors:  Seiichi Nakamura; Jack A Roth; Tapas Mukhopadhyay
Journal:  Oncogene       Date:  2002-04-11       Impact factor: 9.867

6.  DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53.

Authors:  Stéphanie Courtois; Gerald Verhaegh; Sophie North; Maria-Gloria Luciani; Patrice Lassus; Ula Hibner; Moshe Oren; Pierre Hainaut
Journal:  Oncogene       Date:  2002-10-03       Impact factor: 9.867

7.  Regulation of Mdm2-directed degradation by the C terminus of p53.

Authors:  M H Kubbutat; R L Ludwig; M Ashcroft; K H Vousden
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

8.  p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products.

Authors:  Yili Yin; C W Stephen; M Gloria Luciani; Robin Fåhraeus
Journal:  Nat Cell Biol       Date:  2002-06       Impact factor: 28.824

9.  alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome.

Authors:  G K Tofaris; R Layfield; M G Spillantini
Journal:  FEBS Lett       Date:  2001-11-30       Impact factor: 4.124

Review 10.  Antizyme, a mediator of ubiquitin-independent proteasomal degradation.

Authors:  P Coffino
Journal:  Biochimie       Date:  2001 Mar-Apr       Impact factor: 4.079

View more
  30 in total

1.  E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice.

Authors:  Anny Shai; Henry C Pitot; Paul F Lambert
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  HPV E6 proteins target Ubc9, the SUMO conjugating enzyme.

Authors:  Phillip R Heaton; Adeline F Deyrieux; Xue-Lin Bian; Van G Wilson
Journal:  Virus Res       Date:  2011-04-12       Impact factor: 3.303

Review 3.  Virus manipulation of cell cycle.

Authors:  R Nascimento; H Costa; R M E Parkhouse
Journal:  Protoplasma       Date:  2011-10-11       Impact factor: 3.356

4.  Ubiquitin over-expression promotes E6AP autodegradation and reactivation of the p53/MDM2 pathway in HeLa cells.

Authors:  Rita Crinelli; Marzia Bianchi; Michele Menotta; Elisa Carloni; Elisa Giacomini; Marzia Pennati; Mauro Magnani
Journal:  Mol Cell Biochem       Date:  2008-07-09       Impact factor: 3.396

5.  p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes.

Authors:  Thibault Mesplède; David Gagnon; Fanny Bergeron-Labrecque; Ibrahim Azar; Hélène Sénéchal; François Coutlée; Jacques Archambault
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

6.  Susceptibility of p53 unstructured N terminus to 20 S proteasomal degradation programs the stress response.

Authors:  Peter Tsvetkov; Nina Reuven; Carol Prives; Yosef Shaul
Journal:  J Biol Chem       Date:  2009-07-17       Impact factor: 5.157

Review 7.  Ubiquitination involved enzymes and cancer.

Authors:  Mei-juan Zhou; Fang-zhi Chen; Han-chun Chen
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

Review 8.  Ubiquitin-independent proteasomal degradation during oncogenic viral infections.

Authors:  Jiwon Hwang; Laura Winkler; Robert F Kalejta
Journal:  Biochim Biophys Acta       Date:  2011-06-06

9.  Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD.

Authors:  Vjekoslav Tomaic; David Pim; Miranda Thomas; Paola Massimi; Michael P Myers; Lawrence Banks
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

10.  Peptide interactions stabilize and restructure human papillomavirus type 16 E6 to interact with p53.

Authors:  Tina Ansari; Nicole Brimer; Scott B Vande Pol
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.